#United States #Nashville #OneOncology #OneR #ASHMeeting

OneOncology and OneR at the ASH 2025 Annual Meeting

On December 3, 2025, OneOncology and its clinical research management arm, OneR, announced their participation in the upcoming American Society of Hematology (ASH) Annual Meeting scheduled from December 6 to 9. This year, the organizations will present a diverse portfolio of research highlighting the contributions of community-based investigators in the field of hematologic malignancies.

With 25 scientific abstracts—including seven oral presentations and 18 poster presentations—the research underscores the importance of community practices in advancing blood cancer treatment. The findings represent key themes in the areas of targeted therapies, bispecific antibodies, next-generation BTK inhibitors, cellular therapies, and genomic profiling, reflecting the dedication to enhancing patient care through innovative treatment options.

Significance of Community-Based Research

Community-based research sites play a crucial role in accelerating developments in blood cancer therapies. Ian W. Flinn, MD, PhD, Chief Scientific Officer at OneOncology and leader of OneR, stated, "These results show that OneOncology-affiliated practices are delivering critical research directly to patients in their communities." This highlights the necessity of ensuring that cutting-edge therapies become accessible to patients who may otherwise be excluded from research trials.

Key Research Themes

The abstracts presented at ASH 2025 will span a variety of crucial themes:

• - Subcutaneous Bispecific Antibodies: Research indicates these can serve as transformative frontline therapies for treating blood cancers.
• - Cellular Therapies: Expanding the use of CAR-T therapies into more aggressive disease types and vulnerable populations has shown promising early outcomes.
• - Next-Generation BTK Inhibitors: Findings demonstrate durable responses for high-risk patient groups, indicating potential for improved treatment efficacy.
• - Novel Clinical Trials: The studies explore unique designs that could reshape future treatment paradigms, focusing on first-in-human investigations that push the boundaries of current understanding.
• - Genomic Profiling: Enhanced disease assessment and care pathways through predictive tools inform the development of guidelines that strengthen real-world practices.
• - Phase Research Participation: OneR’s robust involvement in early-phase and cell therapy research indicates a commitment to encompassing the entire spectrum of translational research, not limiting participation to late-phase trials alone.

Looking Ahead to ASH 2025

This year's ASH meeting serves as a significant platform for OneOncology and OneR to showcase their contributions to hematology. A comprehensive list of abstracts and the names of the investigators will be available, providing insights into the breadth and depth of research conducted within their network. To arrange interviews with one of the OneR-affiliated researchers during the ASH meeting, interested parties can reach out to Eric Hoffman via email.

As OneOncology continues to drive innovation in patient-centered care, this array of presentations at the ASH 2025 Annual Meeting will not only benefit the medical community but also translate into tangible improvements in treatment outcomes for individuals battling blood cancers. The mission remains clear: empower community practices to deliver high-quality care while enhancing accessibility and lowering costs, thus making a meaningful difference in the lives of patients.